ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 31 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $1,000 | -96.7% | 200 | -97.5% | 0.00% | – |
| Q1 2020 | $30,000 | -94.7% | 7,859 | -91.7% | 0.00% | – |
| Q4 2019 | $568,000 | +1059.2% | 94,276 | +1295.0% | 0.00% | – |
| Q3 2019 | $49,000 | -78.0% | 6,758 | -59.2% | 0.00% | – |
| Q2 2019 | $223,000 | -73.1% | 16,579 | -94.1% | 0.00% | -100.0% |
| Q4 2018 | $830,000 | +3092.3% | 279,500 | +8607.2% | 0.00% | – |
| Q3 2018 | $26,000 | -74.3% | 3,210 | -69.1% | 0.00% | – |
| Q2 2018 | $101,000 | -38.0% | 10,388 | -45.0% | 0.00% | – |
| Q1 2018 | $163,000 | -52.1% | 18,883 | -30.7% | 0.00% | – |
| Q4 2017 | $340,000 | -43.3% | 27,253 | -62.1% | 0.00% | – |
| Q3 2017 | $600,000 | -84.2% | 71,891 | -67.8% | 0.00% | -100.0% |
| Q2 2017 | $3,787,000 | +13925.9% | 223,208 | +5560.9% | 0.00% | – |
| Q2 2016 | $27,000 | +575.0% | 3,943 | +685.5% | 0.00% | – |
| Q1 2016 | $4,000 | -50.0% | 502 | -41.6% | 0.00% | – |
| Q4 2015 | $8,000 | -38.5% | 859 | -9.9% | 0.00% | – |
| Q3 2015 | $13,000 | – | 953 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |